Valganciclovir

Drug Profile

Valganciclovir

Alternative Names: Cymeval; R127; RG 127; RO 1079070/194; RS 079070194; RS 79070; TA-9070; Valcyte; Valgancyclovir; Valixa

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Mitsubishi Tanabe Pharma Corporation; Roche; Stanford University School of Medicine
  • Class Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action Cytomegalovirus replication inhibitors; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus retinitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cytomegalovirus infections; Cytomegalovirus retinitis
  • No development reported Chronic fatigue syndrome
  • Discontinued Ulcerative colitis

Most Recent Events

  • 18 Jul 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-fatigue-syndrome in USA (PO)
  • 20 Nov 2014 First Generic available in USA for Cytomegalovirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top